Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

MINDHUNTER X 60 caps
MINDHUNTER X 60 caps

MINDHUNTER X 60 caps

MINDHUNTER The architecture of the cholinergic stack – acetylcholine synthesis, protection from breakdown and modulation of glutamatergic transmission – supports clear concentration and cognitive work.

71,99 €
With code BLACK: 57,59 € Lowest price in the 30 days before the discount: 71,99 €
Fast shipping
Free delivery from 350 €
Returns policy

MINDHUNTER X 60 caps - nootropic cholinergic formula for advanced users

  • Phenylpiracetam, aniracetam, Alpha-GPC and Huperzine-A.
  • Pack: 60 capsules.
  • Specialized nootropic preparation for adults (21+).

Product status information

A specialized nootropic preparation intended only for adults (21+) who have pharmacological knowledge of the ingredients and accept the risk profile. It is not a dietary supplement in the Polish or EU legal sense — the formula contains racetams (phenylpiracetam, aniracetam), which are not authorized by EFSA as dietary supplement ingredients. Product for self-assessment of risk.

The effectiveness of mental work depends on three things: the availability of acetylcholine (a neurotransmitter of memory and concentration), the efficiency of glutamatergic transmission (speed of information processing) and the stability of central nervous system stimulation (alertness without excessive stimulation). A single nootropic rarely covers all three axes at once. Multi-ingredient formulas are designed so that the mechanisms complement each other – and this is what MINDHUNTER X is based on.

MINDHUNTER X combines four ingredients with complementary effects: two racetams (phenylpiracetam and Aniracetam) modulating AMPA/NMDA transmission and choline uptake, a precursor of acetylcholine (Alpha-GPC) and an inhibitor of its degradation (Huperzine-A). This is the classic “push-pull” architecture of a cholinergic stack: one component provides the substrate, the other protects the product against degradation. A serving (2 capsules) provides 200 mg of phenylpiracetam, 250 mg of aniracetam, 300 mg of Alpha-GPC and 100 mcg of Huperzine-A.

The product is intended for advanced adults working mentally under time pressure – programmers, traders, analysts, people preparing for exams – who are looking for clear, balanced concentration without the “jittery” effect typical of high doses of stimulants.

INTENDED FOR RESEARCH PURPOSES! All the above-mentioned properties are observed in laboratory tests, not performed on humans, they are for information purposes only. All information contained in the descriptions has not been approved by GIS, GIF or EFSA. The substance is not a medicine, food product or dietary supplement and is therefore not suitable for human consumption.

The product qualifies as a chemical reagent/reference material authorized for marketing in the EU. It can only be used for scientific research. Other information about the agent is included in the safety data sheet for the chemical substance, which we make available for viewing. Products are available only to institutions or private individuals associated with research or laboratory activities.

Architecture of the cholinergic stack

Acetylcholine (ACh) is a neurotransmitter critical for working memory, attention, and information consolidation. It is synthesized from choline and acetyl-CoA by the enzyme choline acetyltransferase in cholinergic neurons (Meynert’s nucleus, septal stria, prefrontal cortex, hippocampus) and then broken down in the synaptic cleft by acetylcholinesterase (AChE). The availability of ACh at the synapse depends on two variables: the rate of synthesis (how much substrate) and the rate of degradation (how quickly AChE removes the neurotransmitter).

Racetams – class of nootropics derived from piracetam (developed in the 1960s by UCB Pharma) – act on a different level: they modulate AMPA and NMDA glutamatergic receptors and increase choline uptake into neurons. This second property has an important practical consequence: racetams increase the demand for choline, and substrate deficiency manifests itself in the characteristic “racetam headache” (cholinergic deficit headache).

That’s why a well-designed racetam stack always includes a source of choline – in the case of MINDHUNTER X, it is Alpha-GPC. The architecture of the formula therefore includes four complementary axes: racetams (glutamate transmission + choline uptake) + Alpha-GPC (ACh synthesis) + Huperzine-A (ACh protection against degradation). Each ingredient enhances the action conditions of the others.

Product composition

Serving size (2 capsules) contains:

Active ingredient Quantity in 2 capsules
Phenylpiracetam 200 mg
Aniracetam 250 mg
Alpha-GPC (L-alpha-glycerylphosphorylcholine) 300 mg
Huperzine-A 100 mcg

Packaging: 60 HPMC hard capsules (vegan) = 30 servings. Excipients: microcrystalline cellulose, colloidal silica, magnesium stearate. Coating: hypromellose (HPMC).

Mechanism of action - four components, one goal

Phenylpiracetam – alertness without jitters

Phenylpiracetam (Carphedon, fonturacetam) is a phenyl derivative of piracetam, developed in the USSR in the 1980s as Carphedon – originally for cosmonauts, in the context of psychophysical endurance under stress.

  • CAS: 77472-70-9 · Pattern: C₁₂H₁₄N₂O₂ · Molar mass: 218.25 g/mol
  • Mechanism: the addition of a phenyl group increases lipophilicity (better penetration of the blood-brain barrier) and gives the molecule a psychostimulant profile. Phenylpiracetam increases the density of dopamine receptors (D1, D2, D3) and NMDA and AChR receptors in the cortex; modulates choline uptake in the hippocampus. Improvements in locomotor and memory parameters as well as anticonvulsant activity were observed in rodent models
  • In practice: “bright but not nervous energy” profile – central stimulation without the anxiety component typical of caffeine. This is also the reason why phenylpiracetam is on the WADA list (see “Legal Status”)

Aniracetam – smooth association

Aniracetam is a lipophilic racetam from the ampakine group (positive AMPA modulators).

  • CAS: 72432-10-1 · Pattern: C₁₆H₁₉NO₃ · Molar mass: 273.33 g/mol
  • Mechanism: Aniracetam is a positive allosteric modulator of the AMPA receptor – it slows down its desensitization, prolonging the glutamatergic signal (Ito et al. 1990). It also modulates cholinergic, serotonergic and dopaminergic transmission. The lipophilicity of the molecule provides better CNS penetration than native piracetam
  • In practice: pro-creative profile – enhanced fluency of associations and conceptual work; the anxiolytic component balances the stimulant nature of phenylpiracetam. The short half-life (~1-3 h) makes aniracetam act quickly and does not accumulate

Alpha-GPC – substrate for acetylcholine

Alpha-GPC (L-alpha-glycerylphosphorylcholine) is a highly bioavailable choline donor.

  • CAS: 28319-77-9 · Pattern: C₈H₂₀NO₆P · Molar mass: 257.22 g/mol
  • Mechanism: Alpha-GPC crosses the blood-brain barrier and is hydrolyzed to choline (a substrate for acetylcholine synthesis) and glycerophosphate (a precursor of phosphatidylcholine, a component of the neuron membrane). It increases the concentration of ACh in cholinergic synapses. In the De Jesus Moreno 2003 study (n=261, RCT) Alpha-GPC improved cognitive parameters in mild and moderate dementia
  • In practice: provides choline, the increased demand of which is generated by racetams – it prevents cholinergic deficit and the related headache. Additionally, Alpha-GPC in studies (Kawamura 2012) temporarily increased the secretion of growth hormone in young adults

Huperzine-A – acetylcholine protection

Huperzine-A is an alkaloid from Huperzia serrata, a selective and reversible acetylcholinesterase inhibitor.

  • CAS: 102518-79-6 · Pattern: C₁₅H₁₈N₂O · Molar mass: 242.32 g/mol
  • Mechanism: Huperzine-A inhibits AChE (IC₅₀ ~30-80 nM), blocking the breakdown of acetylcholine in the synaptic cleft. The effect is complementary to Alpha-GPC: while Alpha-GPC increases ACh synthesis, Huperzine-A prolongs its presence at the synapse. This is a “push-pull” mechanism – more neurotransmitter produced, acting longer
  • In practice: stabilizes and prolongs the cholinergic effect of the entire formula, supporting continuity of concentration in longer mental work sessions

Synergy – why four ingredients and not one

The formula is based on two joins:

  1. Racetams ↔ Alpha-GPC — phenylpiracetam and aniracetam increase choline uptake and demand for it; Alpha-GPC provides substrate, preventing cholinergic deficit
  2. Alpha-GPC ↔ Huperzine-A — Alpha-GPC increases the pool of acetylcholine, Huperzine-A slows down its breakdown; together they raise and maintain the concentration of ACh at the synapse

Phenylpiracetam adds a layer of central stimulation (alertness, readiness), Aniracetam – glutamatergic fluidity and anxiolytic component. The designed effect is clear, stable focus without excessive stimulation.

Pharmacological profile

In the literature on individual ingredients and in use reports, reported effects include:

  • Cognitive clarity and alertness — dominant effect; central stimulation without the anxiety component of high doses of caffeine (phenylpiracetam); onset 30-60 minutes after serving
  • Support for working memory and precision processing — cholinergic mechanism (Alpha-GPC + Huperzine-A)
  • Fluency in association and conceptual work — pro-creative component (aniracetam, AMPA modulation)
  • Stability of mental energy — without the sudden “downhill” typical of stimulants; balanced profile

Which the formula doesn’t do (distinction important for advanced users):

  • It is not a classic caffeine/amphetamine stimulant – phenylpiracetam stimulates centrally, but by modulating receptors, not massive release of catecholamines
  • It does not build the effect linearly with the dose – exceeding the dose increases side effects (insomnia, headache), not the cognitive effect
  • Not suitable for daily, indefinite use – phenylpiracetam develops tolerance within 3-5 days of daily exposure

Cyclic use protocol

⚠️ MINDHUNTER X is not suitable for daily, indefinite use. Phenylpiracetam develops tolerance within 3-5 days of daily exposure – the effect wears off and trying to compensate with a higher dose increases the side effects. The formula is intended for use on days requiring intense mental work, not as a daily ritual.

Standard Protocol for Advanced Adults:

Parameter Value
Starting dose (first attempt) 1 capsule (half portion) – tolerance assessment
Standard dose 2 capsules (1 serving) – in the morning or before mental work
Maximum daily dose 2 capsules – do not exceed serving
Frequency 2-4 times a week, on demanding days; not every day
Cycle length maximum 4-6 weeks
Minimal break after the cycle 2-4 weeks

Timing. Take in the morning or at the beginning of a mental work session. Phenylpiracetam has a stimulating profile – administration in the evening disturbs sleep.

Tolerance mechanism. Phenylpiracetam down-regulates dopamine receptors with frequent exposure, which weakens its stimulant effect. Use on demanding days (instead of every day) maintains sensitivity. Huperzine-A also requires cyclic use – chronic AChE inhibition leads to compensatory regulation of cholinergic receptors.

Safety, tolerance, contraindications

Absolute contraindications

  • Pregnancy and breastfeeding
  • Age under 21
  • Epilepsy and reduced seizure threshold (Huperzine-A increases cholinergic transmission; racetams modulate glutamate – potential risk of seizures)
  • Cardiovascular diseases, arrhythmia, hypertension (phenylpiracetam has a central stimulant effect)
  • Bradycardia, sick sinus syndrome (Huperzine-A has a cholinergic effect – it may slow the heart rate)
  • Stomach ulcer (Huperzine-A increases the secretion of gastric juice)
  • Bronchial asthma (cholinergic bronchoconstriction)
  • Psychiatric diseases with an anxiety component or insomnia
  • Current use of AChE inhibitors (donepezil, galantamine, rivastigmine) – additive cholinergic toxicity

Interactions requiring caution

  • Other stimulants (caffeine in high doses, stimulating pre-workouts) — phenylpiracetam sums up central stimulation; risk of overstimulation, tachycardia, anxiety
  • Anticholinergics (atropine, amitriptyline, some antihistamines) — antagonize the action of Alpha-GPC and Huperzine-A
  • AChE inhibitors (dementia drugs) — additive cholinergic effects, risk of cholinergic crisis
  • SSRI/SNRI — aniracetam modulates serotonergic transmission; be careful
  • Anticonvulsants — racetams and Huperzine-A may affect the seizure threshold

Expected side effects (usually mild)

  • Headache (usually from choline deficiency – limited by Alpha-GPC in this formula, but possible with higher sensitivity)
  • Insomnia when taken in the evening (phenylpiracetam)
  • Irritability or agitation when doses are exceeded
  • Nausea, stomach discomfort (cholinergic component of Huperzine-A)

Summary

MINDHUNTER The “push-pull” architecture of the cholinergic stack – ACh synthesis by Alpha-GPC, protection by Huperzine-A, modulation of AMPA/NMDA and choline uptake by racetams – covers four complementary axes of cognitive work. Regulatory status: nootropic preparation for advanced adults (21+), not a dietary supplement; the risk profile requires cyclic use (2-4 times a week, not every day, max 4-6 weeks of the cycle) due to the quick tolerance of phenylpiracetam. Phenylpiracetam is prohibited by WADA (S6) in-competition.

Scientific References

  1. Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70(3):287-312. doi: 10.2165/11319230-000000000-00000. PMID: 20166767. PubMed
  2. Ito I, Tanabe S, Kohda A, Sugiyama H. ​​Allosteric potentiation of quisqualate receptors by the nootropic drug aniracetam. J Physiol. 1990;424:533-43. doi: 10.1113/jphysiol.1990.sp018081. PMID: 1697910. PubMed
  3. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003;25(1):178-93. doi: 10.1016/s0149-2918(03)90023-3. PMID: 12637119. PubMed
  4. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. 2006;27(1):1-26. doi: 10.1111/j.1745-7254.2006.00255.x. PMID: 16364207. PubMed
  5. Kawamura T, Okubo T, Sato K, Fujita S, Goto K, Hamaoka T, Iemitsu M. Glycerophosphocholine enhances growth hormone secretion and fat oxidation in young adults. Nutrition. 2012;28(11-12):1122-6. doi: 10.1016/j.nut.2012.02.011. PMID: 22673596. PubMed